Daniel gained his Biology degree at the University of Granada, the same university where he got a master's degree in Biotechnology. In that academic course, he enjoyed a collaboration grant from the Science Ministry. After obtaining his master's degree, he did a brief internship in the pharmaceutical company Abbott Laboratories.
Currently, he is doing his PhD in Molecular Biology and Biomedicine at Piero Crespo's laboratory, through an FPI contract from Science and Innovation Ministry.
Spatial Regulation of Ras-ERK Signals in Cancer
Research lines
-
Spatial regulation of Ras-ERK signals in physiological processes and in cancer
-
Development of antitumoral drugs targeting protein-protein interactions in the Ras-ERK pathway
Funding
-
“Nuevas dianas moleculares en la ruta Ras-ERK: potencial terapéutico en el cáncer de tiroides”. Asociación Española Contra el Cáncer (AECC). GCB141423113. Proyecto coordinado 2014-2019.
-
Red Temática de Investigación Cooperativa sobre el Cáncer (RTICC). RD/12/0036/0033. 2012-2015.
-
“Proteínas Scaffold como moduladores de la resistencia a inhibidores de la ruta RAS-ERK en melanoma”. SAF-2015 63638R. 2016-2018.
-
Grupo incluido en: Centro de Investigación Biomédica en Red sobre el Cáncer (CIBERONC). (CB16/12/00436). 2017-2023.
-
“ERK spatial distribution and dimerization: implications in carcinogenesis”. RTI2018-096658B. 2019-2021.
-
“Repurposing MAPK inhibitors for the treatment of COVID-19”. Proyecto intramural CSIC. CSIC-COV19-095. 2020.
-
Grupo incluido en la Plataforma PTI SALUD GLOBAL-CSIC: SG2103031_2107300020.
-
“Reutilización de inhibidores de MAPK para el tratamiento de COVID-19”. G.CANTABRIA: 2020UIC22-PUB0008.
-
“Proteínas HOX como mediadores de la ruta RAS-ERK”. PID2021-126288OB-I00. 2022-2025. 294.000€. Investigador Principal.
-
“Desarrollo de un marcador de la respuesta terapéutica del melanoma BRAF positivo”. Proyectos de Prueba de Concepto PDC2022-133569-I00. 2023-2025.
